Abstract: Abstract citation ID: ofad500.2468
1937. Use of Paxlovid for Treatment of Acute COVID-19 and Occurrence of
Post-COVID Conditions among Children and Adults at High-Risk for Severe
COVID-19, April 1 - December 31, 2022
Alexandra F. Dalton, PhD1; Sarah Baca, B.Sc. Environmental Science, B.Sc. Mathematics2;
Julia Raykin, PhD3; Cria Perrine, PhD3; Tegan Boehmer, PhD, MPH1; Emilia Koumans,
MD, MPH3; Priti Patel, MD, MPH1; Sharon Saydah, PhD1; 1Centers for Disease Control
and Prevention, Raleigh, NC; 2GAP Solutions Inc., Austin, Texas; 3CDC, Atlanta, Georgia
Session: 176. Late Breaking Abstracts: COVID-19 & Friends
Friday, October 13, 2023: 2:21 PM
Figure 1. Relative Risk of Post-COVID Conditions among Patients who Received Paxlovid,
Ages ≥50 (N=564,303)
Figure 2. Relative Risk of Post-COVID Conditions among Patients who Received Paxlovid,
Ages 18-49 (N=292,818)
Figure 3. Relative Risk of Post-COVID Conditions among Patients who Received Paxlovid,
Ages 12-17 (N=17,178)
Late Breaking Abstracts • OFID 2023:10 (Suppl 2) • S1269
Background. Data have suggested that treatment with Paxlovid for acute
COVID-19 decreases the incidence of Post-COVID Conditions (PCC); however, results are limited to specific age groups and populations. This analysis assessed the occurrence of PCC following receipt of Paxlovid among children and adults at risk for
severe COVID-19.
Methods. Patients aged ≥ 12 years with COVID-19 (defined by ICD-10 code,
positive SARS-CoV-2 test, or Paxlovid prescription) and at increased risk for severe
COVID-19 due to age, underlying conditions, or immune-suppressing medications,
were identified in HealthVerity claims data. Eligible persons had an outpatient, telehealth, or emergency department encounter for COVID-19 between April 1 – August
31, 2022. Exclusions included liver disease, end-stage renal disease, a prescription for
contraindicated medications, pregnancy in the previous year, or death within 60 days.
Case patients received a Paxlovid prescription within ±5 days of the index date; control patients matched on age, sex, month, and region did not receive Paxlovid within
±5 days. Cases and controls were matched 1:2. Analysis was conducted separately for
3 age groups: 12-17 years, 18-49 years, and ≥50 years. PCC was defined as new conditions > 60 days after index date and prior to December 31, 2022. We calculated the
relative risk (RR) of two overall PCC indicators (≥ 1 or ≥ 2 conditions) and 45 individual conditions.
Results. Among adults aged ≥ 50 years, the risks of overall and individual PCCs
were generally lower among case- than control patients (RR for ≥1 condition=0.92,
95% CI=0.91-0.93; Figure 1). There was no overall difference in risk among adults
18-49; the RR of individual conditions varied (Figure 2). Among adolescents, the risks
of overall and individual PCCs were higher among case than control patients (RR for
≥1 condition=1.07, 95% CI=1.02-1.12; Figure 3).
Conclusion. The results suggest that Paxlovid helps reduce occurrence of PCC in
adults aged ≥ 50 years. Among younger adults and adolescents, associations were observed for only certain conditions. This may be due to a difference in baseline health in
these age groups. Further investigation may help clarify whether Paxlovid provides
benefits in reducing PCC in addition to severity of acute COVID-19.
Disclosures. Priti Patel, MD, MPH, Pfizer:..
{ 'indexed': { 'date-parts': [[2023, 11, 27]],
'date-time': '2023-11-27T05:18:30Z',
'timestamp': 1701062310032},
'reference-count': 0,
'publisher': 'Oxford University Press (OUP)',
'issue': 'Supplement_2',
'license': [ { 'start': { 'date-parts': [[2023, 11, 27]],
'date-time': '2023-11-27T00:00:00Z',
'timestamp': 1701043200000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0/'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2023, 11, 27]]},
'abstract': '<jats:title>Abstract</jats:title>\n'
' <jats:sec>\n'
' <jats:title>Background</jats:title>\n'
' <jats:p>Data have suggested that treatment with Paxlovid for acute COVID-19 '
'decreases the incidence of Post-COVID Conditions (PCC); however, results are limited to '
'specific age groups and populations. This analysis assessed the occurrence of PCC following '
'receipt of Paxlovid among children and adults at risk for severe COVID-19.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Methods</jats:title>\n'
' <jats:p>Patients aged ≥ 12 years with COVID-19 (defined by ICD-10 code, '
'positive SARS-CoV-2 test, or Paxlovid prescription) and at increased risk for severe COVID-19 '
'due to age, underlying conditions, or immune-suppressing medications, were identified in '
'HealthVerity claims data. Eligible persons had an outpatient, telehealth, or emergency '
'department encounter for COVID-19 between April 1 – August 31, 2022. Exclusions included '
'liver disease, end-stage renal disease, a prescription for contraindicated medications, '
'pregnancy in the previous year, or death within 60 days. Case patients received a Paxlovid '
'prescription within ±5 days of the index date; control patients matched on age, sex, month, '
'and region did not receive Paxlovid within ±5 days. Cases and controls were matched 1:2. '
'Analysis was conducted separately for 3 age groups: 12-17 years, 18-49 years, and ≥50 years. '
'PCC was defined as new conditions &gt; 60 days after index date and prior to December 31, '
'2022. We calculated the relative risk (RR) of two overall PCC indicators (≥ 1 or ≥ 2 '
'conditions) and 45 individual conditions.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Results</jats:title>\n'
' <jats:p>Among adults aged ≥ 50 years, the risks of overall and individual '
'PCCs were generally lower among case- than control patients (RR for ≥1 condition=0.92, 95% '
'CI=0.91-0.93; Figure 1). There was no overall difference in risk among adults 18-49; the RR '
'of individual conditions varied (Figure 2). Among adolescents, the risks of overall and '
'individual PCCs were higher among case than control patients (RR for ≥1 condition=1.07, 95% '
'CI=1.02-1.12; Figure 3).Figure 1.Relative Risk of Post-COVID Conditions among Patients who '
'Received Paxlovid, Ages ≥50 (N=564,303)Figure 2.Relative Risk of Post-COVID Conditions among '
'Patients who Received Paxlovid, Ages 18-49 (N=292,818)Figure 3.Relative Risk of Post-COVID '
'Conditions among Patients who Received Paxlovid, Ages 12-17 (N=17,178)</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Conclusion</jats:title>\n'
' <jats:p>The results suggest that Paxlovid helps reduce occurrence of PCC in '
'adults aged ≥ 50 years. Among younger adults and adolescents, associations were observed for '
'only certain conditions. This may be due to a difference in baseline health in these age '
'groups. Further investigation may help clarify whether Paxlovid provides benefits in reducing '
'PCC in addition to severity of acute COVID-19.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Disclosures</jats:title>\n'
' <jats:p>Priti Patel, MD, MPH, Pfizer: Stocks/Bonds</jats:p>\n'
' </jats:sec>',
'DOI': '10.1093/ofid/ofad500.2468',
'type': 'journal-article',
'created': { 'date-parts': [[2023, 11, 27]],
'date-time': '2023-11-27T02:17:17Z',
'timestamp': 1701051437000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': '1937. Use of Paxlovid for Treatment of Acute COVID-19 and Occurrence of Post-COVID Conditions '
'among Children and Adults at High-Risk for Severe COVID-19, April 1 - December 31, 2022',
'prefix': '10.1093',
'volume': '10',
'author': [ { 'given': 'Alexandra F',
'family': 'Dalton',
'sequence': 'first',
'affiliation': [{'name': 'Centers for Disease Control and Prevention , Raleigh, NC'}]},
{ 'given': 'Sarah',
'family': 'Baca',
'sequence': 'additional',
'affiliation': [{'name': 'GAP Solutions Inc. , Austin, Texas'}]},
{ 'given': 'Julia',
'family': 'Raykin',
'sequence': 'additional',
'affiliation': [{'name': 'CDC , Atlanta , Georgia'}]},
{ 'given': 'Cria',
'family': 'Perrine',
'sequence': 'additional',
'affiliation': [{'name': 'CDC , Atlanta , Georgia'}]},
{ 'given': 'Tegan',
'family': 'Boehmer',
'sequence': 'additional',
'affiliation': [{'name': 'Centers for Disease Control and Prevention , Raleigh, NC'}]},
{ 'given': 'Emilia',
'family': 'Koumans',
'sequence': 'additional',
'affiliation': [{'name': 'CDC , Atlanta , Georgia'}]},
{ 'given': 'Priti',
'family': 'Patel',
'sequence': 'additional',
'affiliation': [{'name': 'Centers for Disease Control and Prevention , Raleigh, NC'}]},
{ 'given': 'Sharon',
'family': 'Saydah',
'sequence': 'additional',
'affiliation': [{'name': 'Centers for Disease Control and Prevention , Raleigh, NC'}]}],
'member': '286',
'published-online': {'date-parts': [[2023, 11, 27]]},
'container-title': 'Open Forum Infectious Diseases',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.2468/53773788/ofad500.2468.pdf',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'syndication'},
{ 'URL': 'https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.2468/53773788/ofad500.2468.pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2023, 11, 27]],
'date-time': '2023-11-27T02:17:18Z',
'timestamp': 1701051438000},
'score': 1,
'resource': { 'primary': { 'URL': 'https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofad500.2468/7448238'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 11, 27]]},
'references-count': 0,
'journal-issue': {'issue': 'Supplement_2', 'published-print': {'date-parts': [[2023, 11, 27]]}},
'URL': 'http://dx.doi.org/10.1093/ofid/ofad500.2468',
'relation': {},
'ISSN': ['2328-8957'],
'subject': [],
'published-other': {'date-parts': [[2023, 12]]},
'published': {'date-parts': [[2023, 11, 27]]}}
